The role of dasatinib in the management of chronic myeloid leukemia

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous treatment. It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhe, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330036/
https://www.ncbi.nlm.nih.gov/pubmed/25709401
http://dx.doi.org/10.2147/DDDT.S80207